The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device).

The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.

Inclusion Criteria:

• Male and females greater than or equal to 18 years of age
• Diagnosis of RRMS according to revised McDonald Criteria (2010) or (CIS)
• Prescribed BETASERON (note: decision to treat with BETASERON must be made independent of participation in this study)
• Confirmation of insurance coverage for BETASERON treatment
• Access to a personal computer to complete online patient satisfaction survey at Week 6

Exclusion Criteria:

• Currently enrolled in a clinical trial or other observational study for Multiple Sclerosis treatment
• Documented substance abuse within the previous 6 months prior to study enrollment
• Any major laboratory value abnormality that the investigator believes would preclude the patient from participating in the study
• Any medical disorder, condition or history that in the opinion of the investigator would impair the patient's ability to participate in or complete the study
• Pregnant or nursing

Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS)